Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.

Sartorius has agreed to invest $3m in Nanotein Technologies, engaged in the development of advanced immune cell activation reagents.

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research Act.

As tariffs on drug imports from the EU look set to alter pricing and manufacturing strategies, each entity needs to study its full impact.

Denny Bros will be attending London Packaging Week 2025 on the 15th and 16th of October, and their booth number is C84.

Biostar Stem Cell Technology Research Institute has received Japan's MHLW approval for its angel stem cell therapy for ASD.

Boehringer's Hernexeos is now FDA-approved for patients with HER2-positive NSCLC, bringing it into direct competition with ADC Enhertu.

Arvinas, in collaboration with Pfizer, has announced vepdegestrant NDA acceptance by the FDA for breast cancer treatment.

The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery market.